Impact of socioeconomic status on treatment outcome in patients with advanced esophagogastric cancer in Northern Ireland

摘要: e20531 Background: The survival advantage for combination chemotherapy in advanced gastroesophageal adenocarcinoma is well documented. Epirubicin and cisplatin with either 5FU (ECF) or capecitabine (ECX) result response rates of 35–46% a median around 9 months RCT. We report the impact socioeconomic status on outcome ECF ECX treatment cancer patients Northern Ireland between 2000 2007. Methods: All esophageal (O), gastric (G), esophagogastric junction (OGJ) adenocarcinoma, receiving palliative from January to August 2007, were identified our institutional database. Baseline demographics, clinical characteristics, details, outcomes recorded. Patients trial excluded. Survival was estimated using Kaplan-Meier method. Deprivation assessed patient's home address deprivation index (DPI) (Nor...